Adam Waxman

Dr. Adam Waxman is an Assistant Professor of Clinical Medicine in the Hematology-Oncology division at the Perelman School of Medicine, University of Pennsylvania. He practices at the Abramson Cancer Center and holds hospital privileges at the Hospital of the University of Pennsylvania. Dr. Waxman completed his medical training at Duke University School of Medicine and his residency and fellowship at the Hospital of the University of Pennsylvania.

Dr. Waxman's research focuses on hematologic malignancies, with particular emphasis on multiple myeloma and amyloidosis. His work investigates novel immunotherapies including teclistamab and CAR T-cell therapy, as well as treatment complications and outcomes. His recent publications examine the safety and efficacy of teclistamab for multiple myeloma and AL amyloidosis, secondary malignancies following cellular therapies, and mechanisms of disease progression.

Analysis of Dr. Waxman's recent publications (2023-2025) reveals a strong focus on clinical applications of novel immunotherapies for blood cancers. His work spans both clinical outcomes research and translational studies, with significant contributions to understanding teclistamab therapy, CAR T-cell complications, and treatment-related adverse events in multiple myeloma and amyloidosis.

Dr. Waxman maintains an active clinical practice specializing in hematology-oncology at the Abramson Cancer Center, where he treats patients with complex blood disorders. His work bridges clinical care and research, contributing to the advancement of treatments for hematologic malignancies through both patient care and scholarly contributions to the field.